Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
Go back to Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 198.91 -1.45 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $200.36 | 52 Week High | $333.65 | |||
| Open | $198.92 | 52 Week Low | $223.02 | |||
| Day High | $201.01 | P/E | 25.47 | |||
| Day Low | $196.00 | EPS | $7.81 | |||
| Volume | 1,657,524 | |||||
